NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has inked a licensing deal that permits Axela to develop assays that measure Proteome Sciences' brain damage biomarkers on Axela's multiplex biomarker assay dotLab system.
The agreement includes an option for Axela to license the developed assays for research and diagnostic uses.
Cobham, UK-based Proteome Sciences has a portfolio of blood biomarkers of brain damage-related disorders it developed in a collaboration with the Biomedical Proteomics Research Group at the University of Geneva. These conditions include stroke, traumatic brain injury, subarachnoid hemorrhage, and neurodegenerative disorders such as Parkinson's, ALS, and Alzheimer's disease.
Axela CEO Rocky Ganske said in a statement that the company's technology "is particularly suited to brain injury testing where rapid and accurate quantitation of protein biomarker panels is vital."
Proteome Sciences' MS Biomarker Assay system uses the company's isobaric Tandem Mass Tags and reference materials combined with isotope dilution mass spectrometry. The firm provides biomarker discovery and validation services, as well as assay development services.
Financial terms of the agreement were not released.